Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19Business Wire • 07/31/20
Quidel Corporation (QDEL) CEO Peter Ingram on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 07/29/20
Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 07/29/20
Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/23/20
Published National Findings in Lyme Disease Testing to Be Discussed on July 30 Webinar Hosted by Quidel CorporationBusiness Wire • 07/21/20
These 3 Stocks Near All-Time Highs Will Be Dangerous When the Next Crash ComesThe Motley Fool • 07/19/20
Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 InstrumentsBusiness Wire • 07/18/20
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020Business Wire • 07/13/20